pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 34 Non-oncology: 23
Oncology: 11
Under Consideration for Negotiation 25 Non-oncology: 18
Oncology: 7
Completed Negotiations 420 With Letter of Intent: 362
Without agreement: 58
Negotiations That Were Not Pursued 81

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Rozlytrek HOFFMANN-LA ROCHE LIMITED ROS1-positive Non-Small Cell Lung Cancer
Mayzent NOVARTIS PHARMACEUTICALS CANADA INC Secondary progressive multiple sclerosis (SPMS)
Stelara Janssen Inc. Ulcerative Colitis
Beovu Novartis Pharma Canada Inc. Age-Related Macular Degeneration
Trurapi SANOFI-AVENTIS Diabetes Mellitus, Type 1 & 2

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Adcetris Seattle Genetics Inc. Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)
Adcetris Seattle Genetics Inc. Hodgkin's Lymphoma
Inclunox Sandoz Canada Inc. Deep vein thrombosis (treatment and prevention)

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Xultophy Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks